Ser73
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser73  -  Jun (human)

Site Information
VGLLkLAsPELERLI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447943

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 95 , 97 , 101 ) , [32P] bio-synthetic labeling ( 99 , 102 , 103 ) , electrophoretic mobility shift ( 102 ) , flow cytometry ( 1 ) , immunoprecipitation ( 4 , 5 , 17 , 45 , 95 , 97 , 101 , 103 ) , mass spectrometry ( 2 , 6 , 7 , 8 , 9 , 12 , 13 , 14 , 15 , 16 , 18 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 32 , 33 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 67 , 70 , 72 , 74 , 75 , 76 , 80 , 84 ) , mutation of modification site ( 66 , 73 , 83 , 85 , 86 , 91 , 92 , 94 , 95 , 97 , 98 , 99 , 101 , 102 , 103 ) , peptide sequencing ( 55 ) , phospho-antibody ( 1 , 4 , 5 , 10 , 11 , 17 , 21 , 29 , 30 , 31 , 34 , 35 , 45 , 57 , 68 , 69 , 71 , 73 , 77 , 78 , 79 , 82 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 95 , 96 , 103 ) , phosphoamino acid analysis ( 66 ) , phosphopeptide mapping ( 97 , 99 , 101 , 102 ) , western blotting ( 1 , 4 , 5 , 10 , 11 , 17 , 21 , 29 , 30 , 31 , 34 , 35 , 45 , 55 , 57 , 66 , 68 , 69 , 71 , 73 , 78 , 79 , 86 , 88 , 95 , 97 , 101 , 103 )
Disease tissue studied:
adrenal cancer ( 99 ) , pheochromocytoma ( 99 ) , bladder cancer ( 1 ) , bone cancer ( 66 , 78 ) , breast cancer ( 6 , 13 , 14 , 23 , 24 , 30 , 55 , 57 ) , breast ductal carcinoma ( 13 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 13 ) , cervical cancer ( 60 ) , cervical adenocarcinoma ( 60 ) , colorectal cancer ( 5 , 17 , 45 , 71 ) , colorectal carcinoma ( 5 , 17 , 45 , 71 ) , gastric cancer ( 42 , 43 , 46 , 47 , 51 ) , gastric carcinoma ( 42 , 43 , 46 , 47 , 51 ) , leukemia ( 33 , 34 , 54 , 59 , 74 ) , chronic myelogenous leukemia ( 54 , 59 , 74 ) , T cell leukemia ( 33 , 34 ) , liver cancer ( 55 , 103 ) , lung cancer ( 4 , 16 , 24 , 38 , 50 , 55 , 70 , 71 ) , non-small cell lung cancer ( 4 , 24 , 50 , 55 , 70 , 71 ) , non-small cell lung adenocarcinoma ( 4 , 16 , 50 ) , non-small cell squamous cell lung carcinoma ( 50 , 71 ) , lymphoma ( 35 , 102 , 103 ) , anaplastic large cell lymphoma ( 35 ) , neuroblastoma ( 22 ) , ovarian cancer ( 13 , 80 ) , pancreatic ductal adenocarcinoma ( 15 ) , prostate cancer ( 21 , 55 ) , melanoma skin cancer ( 9 , 31 , 80 ) , testicular cancer ( 99 , 103 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 32 ) , 'neuron, cerebellar granule'-brain ( 89 ) , 'pancreatic, ductal'-pancreas ( 15 ) , 'stem, embryonic' ( 63 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 41 ) , 293 (epithelial) [AT1 (human), transfection] ( 39 ) , 293 (epithelial) ( 4 , 5 , 11 , 29 , 45 , 65 , 66 , 77 , 78 , 86 , 88 , 94 , 97 ) , 293GP (epithelial) [NPM-ALK (human), transfection] ( 40 ) , 308 (keratinocyte) ( 96 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 83 ) , 786-O (renal) [VHL (human), transfection] ( 7 ) , A375 (melanocyte) ( 31 ) , A431 (epithelial) ( 99 ) , A498 (renal) ( 44 ) , A549 (pulmonary) ( 4 , 71 ) , breast ( 2 , 13 ) , breast cell-breast ( 92 ) , BT-20 (breast cell) ( 24 , 55 ) , BT-549 (breast cell) ( 24 ) , CEF ( 95 ) , CL1-2 (pulmonary) ( 38 ) , CL1-5 (pulmonary) ( 38 ) , COV413 (ovarian) ( 80 ) , DM331 (melanocyte) ( 80 ) , endothelial-aorta ( 25 ) , epithelial-corneal ( 69 ) , F9 (testicular) ( 99 , 103 ) , fibroblast-foreskin [HRas (human)] ( 90 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 27 ) , Flp-In T-Rex-293 (epithelial) ( 27 ) , Fr 3T3 (fibroblast) ( 101 ) , GM00637 (lymphoblast) ( 98 ) , H2009 (pulmonary) ( 24 ) , H2077 (pulmonary) ( 24 ) , H2887 (pulmonary) ( 24 ) , H322M (pulmonary) ( 24 ) , HaCaT (keratinocyte) ( 78 ) , HCC1359 (pulmonary) ( 24 ) , HCC1937 (breast cell) ( 24 , 57 ) , HCC2279 (pulmonary) ( 24 ) , HCC366 (pulmonary) ( 24 ) , HCC4006 (pulmonary) ( 24 ) , HCC78 (pulmonary) ( 24 ) , HCC827 (pulmonary) ( 24 ) , HCT116 (intestinal) ( 17 , 45 , 71 ) , HEK293T (epithelial) ( 8 , 79 , 83 ) , HeLa (cervical) ( 12 , 20 , 21 , 37 , 48 , 49 , 52 , 68 , 72 , 84 , 92 , 98 , 101 ) , HeLa S3 (cervical) ( 60 ) , HepG2 (hepatic) ( 55 , 103 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 14 ) , HMLER ('stem, breast cancer') ( 14 ) , HOP62 (pulmonary) ( 24 ) , HT-29 (intestinal) ( 5 ) , HUES-7 ('stem, embryonic') ( 62 ) , HUES-9 ('stem, embryonic') ( 36 ) , HUVEC (endothelial) ( 91 ) , JB-6 (lymphocyte) ( 35 ) , JB6 CI41 (epidermal) ( 66 ) , Jurkat (T lymphocyte) ( 18 , 34 , 53 , 58 , 67 , 75 , 76 , 101 ) , K562 (erythroid) ( 20 , 54 , 59 , 61 , 74 ) , keratinocyte ( 78 ) , Kit225 (T lymphocyte) ( 33 ) , LCLC-103H (pulmonary) ( 24 ) , LNCaP (prostate cell) ( 21 , 55 ) , LOU-NH91 (squamous) ( 24 ) , LoVo (intestinal) ( 55 ) , lung ( 16 ) , MCF-7 (breast cell) ( 6 , 24 , 30 , 55 , 87 , 92 ) , MDA-MB-231 (breast cell) ( 24 ) , MDA-MB-468 (breast cell) ( 24 ) , MEF (fibroblast) ( 1 , 73 ) , MKN-45 (gastric) ( 26 , 42 , 43 , 46 , 47 , 51 ) , MRC5 (fibroblast) ( 73 , 93 ) , MV4-11 (macrophage) ( 64 ) , NB10 (neural crest) ( 22 ) , NCI-H1299 (pulmonary) ( 70 , 71 ) , NCI-H1395 (pulmonary) ( 24 ) , NCI-H1568 (pulmonary) ( 24 ) , NCI-H157 (pulmonary) ( 24 ) , NCI-H1650 (pulmonary) ( 71 ) , NCI-H1666 (pulmonary) ( 24 ) , NCI-H1703 (squamous) ( 26 , 50 , 71 ) , NCI-H2030 (pulmonary) ( 24 ) , NCI-H2172 (pulmonary) ( 24 ) , NCI-H23 (pulmonary) ( 71 ) , NCI-H322 (pulmonary) ( 24 ) , NCI-H3255 (pulmonary) ( 26 ) , NCI-H460 (pulmonary) ( 24 , 71 ) , NCI-H520 (squamous) ( 24 ) , NCI-H647 (pulmonary) ( 24 ) , NPC (neural crest) ( 22 ) , NSCLC (pulmonary) ( 55 ) , ovary ( 13 ) , PC-12 (chromaffin) ( 99 ) , PC9 (pulmonary) ( 24 ) , Saos-2 (bone cell) ( 66 ) , SH-SY5Y (neural crest) ( 85 ) , SHEP (neuron) ( 85 ) , SKBr3 (breast cell) ( 23 , 55 ) , T24 (bladder cell) ( 1 ) , T98G (glial) ( 82 ) , U-937 (myeloid) ( 102 , 103 ) , U2OS (bone cell) ( 56 , 78 ) , UMUC3 (bladder cell) ( 1 ) , WM239A (melanocyte) ( 9 )

Upstream Regulation
Regulatory protein:
BMF (human) ( 31 ) , CDCA4 (human) ( 68 ) , CDK3 (human) ( 66 ) , HER4 (human) ( 79 ) , HRas (human) ( 79 ) , LKB1 (human) ( 71 ) , MEKK1 (human) ( 86 ) , MST2 (human) ( 57 ) , NFkB-p100 (human) ( 1 ) , PRKD1 (human) ( 27 ) , PRR7 (human) ( 34 ) , RALA (human) ( 94 ) , ROCK1 (human) ( 78 ) , XIAP (human) ( 17 )
Putative in vivo kinases:
CDK3 (human) ( 5 , 66 ) , ERK1 (human) ( 103 ) , ERK2 (human) ( 103 ) , ERK7 (human) ( 45 ) , JNK1 (human) ( 81 , 87 , 98 , 101 ) , PBK (human) ( 4 ) , PLK3 (human) ( 69 ) , VRK1 (human) ( 83 )
Kinases, in vitro:
CDK3 (human) ( 5 , 66 ) , ERK1 (human) ( 103 ) , ERK2 (human) ( 103 ) , ERK7 (human) ( 45 ) , JNK1 (human) ( 29 , 66 , 98 , 100 , 101 ) , JNK2 (human) ( 98 ) , PBK (human) ( 4 ) , VRK1 (human) ( 83 )
Putative upstream phosphatases:
PPP2CA (human) ( 17 )
Treatments:
4-HT ( 55 ) , adriamycin ( 30 ) , AG1478 ( 55 ) , angiotensin_2 ( 41 ) , anti-TCR ( 34 ) , beta-glycerophosphate ( 103 ) , bryostatin_1 ( 102 ) , BSO ( 93 ) , CCT007093 ( 21 ) , Cd(2+) ( 93 ) , cobalt ( 69 ) , dasatinib ( 61 ) , EGF ( 35 , 45 , 66 , 79 ) , EKI-785 ( 66 ) , etoposide ( 77 ) , faslodex ( 55 ) , hypoxia ( 69 ) , hypoxia/reoxygenation ( 69 ) , IL-1a ( 73 ) , ionizing_radiation ( 21 , 93 ) , ischemia ( 13 ) , JNK_inhibitor_I ( 79 ) , kainic_acid ( 11 ) , lapatinib ( 23 ) , LY294002 ( 31 , 79 ) , metastatic potential ( 38 ) , MMS ( 98 ) , NAC ( 93 ) , nocodazole ( 60 ) , okadaic_acid ( 17 , 96 , 102 ) , PD98059 ( 55 , 66 , 79 ) , phorbol_ester ( 68 , 88 , 97 , 101 , 102 , 103 ) , PLX4720 ( 31 ) , SB203580 ( 31 , 79 , 89 ) , serum ( 45 ) , serum_withdrawal ( 89 ) , SII_angiotensin_2 ( 39 ) , siRNA ( 66 , 68 , 71 ) , SNP ( 85 ) , SP600125 ( 31 , 55 , 66 , 88 ) , TAK1_inhibitor ( 10 ) , TNF ( 90 ) , U0126 ( 31 ) , UV ( 68 , 69 , 78 , 85 , 95 , 101 ) , vemurafenib ( 9 ) , WR1065 ( 87 ) , Y27632 ( 78 )

Downstream Regulation
Effects of modification on Jun:
acetylation ( 73 ) , activity, induced ( 66 , 83 , 89 , 92 , 94 , 96 , 99 , 101 ) , enzymatic activity, induced ( 103 ) , molecular association, regulation ( 73 , 92 , 97 , 101 ) , protein stabilization ( 83 )
Effects of modification on biological processes:
carcinogenesis, induced ( 17 ) , cell cycle regulation ( 17 ) , cell growth, altered ( 66 ) , cell growth, induced ( 17 ) , cell motility, induced ( 5 ) , transcription, altered ( 45 , 66 , 86 ) , transcription, induced ( 4 , 5 , 17 , 73 , 83 , 91 , 94 , 98 , 99 , 102 , 103 )
Induce interaction with:
DNA ( 73 ) , NFkB-p65 (human) ( 73 ) , PIN1 (human) ( 92 )
Inhibit interaction with:
DNA ( 97 ) , HDAC3 (human) ( 73 ) , JNK1 (human) ( 101 )

Disease / Diagnostics Relevance
Relevant diseases:
ovarian cancer ( 80 ) , melanoma skin cancer ( 80 )

References 

1

Xu J, et al. (2016) Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100). Oncotarget 7, 34112-30
27095572   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Li Y, et al. (2016) TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun. Oncotarget 7, 6748-64
26745678   Curated Info

5

Lu J, et al. (2016) Cdk3-promoted epithelial-mesenchymal transition through activating AP-1 is involved in colorectal cancer metastasis. Oncotarget 7, 7012-28
26755651   Curated Info

6

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

7

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

8

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

9

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

10

Huang HL, Chiang CH, Hung WC, Hou MF (2015) Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer. Oncotarget 6, 995-1007
25557171   Curated Info

11

Zhu QJ, et al. (2014) Tyrosine phosphorylation of GluK2 up-regulates kainate receptor-mediated responses and downstream signaling after brain ischemia. Proc Natl Acad Sci U S A 111, 13990-5
25201974   Curated Info

12

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

13

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

14

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

15

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

16

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

17

Cao Z, et al. (2013) X-linked Inhibitor of Apoptosis Protein (XIAP) Regulation of Cyclin D1 Protein Expression and Cancer Cell Anchorage-independent Growth via Its E3 Ligase-mediated Protein Phosphatase 2A/c-Jun Axis. J Biol Chem 288, 20238-47
23720779   Curated Info

18

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

19

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

20

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

21

Song JY, et al. (2013) Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to γ-radiation. Cell Death Dis 4, e744
23907458   Curated Info

22

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

23

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

24

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

25

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

26

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

27

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

28

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

29

Huang J, et al. (2012) The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542-6
22327296   Curated Info

30

Ho KK, et al. (2012) Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem 287, 1545-55
22128155   Curated Info

31

Shao Y, Aplin AE (2012) ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis 3, e253
22258404   Curated Info

32

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

33

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

34

Hrdinka M, et al. (2011) PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. J Biol Chem 286, 19617-29
21460222   Curated Info

35

Li T, et al. (2011) P21-activated protein kinase (PAK2)-mediated c-Jun phosphorylation at 5 threonine sites promotes cell transformation. Carcinogenesis 32, 659-66
21177766   Curated Info

36

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

37

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

38

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

39

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

40

Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32
20393185   Curated Info

41

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

42

Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

43

Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

44

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

45

Xu YM, et al. (2010) Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. Cancer Res 70, 3218-27
20395206   Curated Info

46

Moritz A (2010) CST Curation Set: 9280; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

47

Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

48

Moritz A (2010) CST Curation Set: 9244; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

49

Moritz A (2010) CST Curation Set: 9238; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

50

Moritz A (2010) CST Curation Set: 9241; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

52

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

53

Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

54

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Madeo A, et al. (2010) c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 29, 978-91
19935718   Curated Info

56

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

57

Romano D, et al. (2010) Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res 70, 1195-203
20086174   Curated Info

58

Moritz A (2010) CST Curation Set: 8865; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Moritz A (2010) CST Curation Set: 8864; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

60

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

61

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

62

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

63

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

64

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

65

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

66

Cho YY, et al. (2009) Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res 69, 272-81
19118012   Curated Info

67

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

68

Tategu M, Nakagawa H, Hayashi R, Yoshida K (2008) Transcriptional co-factor CDCA4 participates in the regulation of JUN oncogene expression. Biochimie 90, 1515-22
18572021   Curated Info

69

Wang L, Gao J, Dai W, Lu L (2008) Activation of Polo-like kinase 3 by hypoxic stresses. J Biol Chem 283, 25928-35
18650425   Curated Info

70

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

71

Zhong D, et al. (2008) LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 68, 7270-7
18794113   Curated Info

72

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

73

Wolter S, et al. (2008) c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene. Mol Cell Biol 28, 4407-23
18443042   Curated Info

74

Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

75

Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

76

Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Vinciguerra M, et al. (2008) Negative charged threonine 95 of c-Jun is essential for c-Jun N-terminal kinase-dependent phosphorylation of threonine 91/93 and stress-induced c-Jun biological activity. Int J Biochem Cell Biol 40, 307-16
17920329   Curated Info

78

Ongusaha PP, et al. (2008) Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 1, ra14
19036714   Curated Info

79

Chen SL, et al. (2007) ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein. Oncogene 26, 42-53
16819515   Curated Info

80

Zarling AL, et al. (2006) Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A 103, 14889-94
17001009   Curated Info

81

Sunayama J, Tsuruta F, Masuyama N, Gotoh Y (2005) JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170, 295-304
16009721   Curated Info

82

Wei W, et al. (2005) The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33
16023596   Curated Info

83

Sevilla A, et al. (2004) c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene 23, 8950-8
15378002   Curated Info

84

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info

85

Li L, Feng Z, Porter AG (2004) JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells. J Biol Chem 279, 4058-65
14617628   Curated Info

86

Weiss C, et al. (2003) JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J 22, 3686-95
12853483   Curated Info

87

Pluquet O, et al. (2003) The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem 278, 11879-87
12531896   Curated Info

88

Jiang G, et al. (2003) Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. J Biol Chem 278, 180-6
12409308   Curated Info

89

Coffey ET, et al. (2002) c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J Neurosci 22, 4335-45
12040039   Curated Info

90

Wang W, et al. (2002) Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22, 3389-403
11971971   Curated Info

91

Alfranca A, et al. (2002) c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 22, 12-22
11739718   Curated Info

92

Wulf GM, et al. (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20, 3459-72
11432833   Curated Info

93

Lee SA, Dritschilo A, Jung M (2001) Role of ATM in oxidative stress-mediated c-Jun phosphorylation in response to ionizing radiation and CdCl2. J Biol Chem 276, 11783-90
11278277   Curated Info

94

Okan E, Drewett V, Shaw PE, Jones P (2001) The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism. Oncogene 20, 1816-24
11313929   Curated Info

95

Ui M, et al. (1998) Biochemical and functional analysis of highly phosphorylated forms of c-Jun protein. FEBS Lett 429, 289-94
9662434   Curated Info

96

Peng J, Bowden GT, Domann FE (1997) Activation of AP-1 by okadaic acid in mouse keratinocytes associated with hyperphosphorylation of c-jun. Mol Carcinog 18, 37-43
9022811   Curated Info

97

Papavassiliou AG, Treier M, Bohmann D (1995) Intramolecular signal transduction in c-Jun. EMBO J 14, 2014-9
7744008   Curated Info

98

van Dam H, et al. (1995) ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 14, 1798-811
7737130   Curated Info

99

Deng T, Karin M (1994) c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 371, 171-5
8072547   Curated Info

100

Dérijard B, et al. (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025-37
8137421   Curated Info

101

Hibi M, et al. (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7, 2135-48
8224842   Curated Info

102

Franklin CC, et al. (1992) Phorbol ester-induced amino-terminal phosphorylation of human JUN but not JUNB regulates transcriptional activation. Proc Natl Acad Sci U S A 89, 7247-51
1496019   Curated Info

103

Pulverer BJ, et al. (1991) Phosphorylation of c-jun mediated by MAP kinases. Nature 353, 670-4
1922387   Curated Info